Oral PDE5 drug shows split Phase 3 results at Boston Alzheimer’s conference
Boston — November 17, 2026.
An experimental once-daily pill chemically related to erectile dysfunction drugs slowed cognitive and functional decline by 31% in early Alzheimer’s patients who were not taking standard background dementia medications—even as the drug fell short of statistical significance across the trial’s full patient population, according to The Washington Post, The Independent, and Daily Mail.
South Korean developer AriBio presented topline data from its global Phase 3 POLARIS-AD trial at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, The Telegraph and LBC reported. The drug, known as AR1001 (mirodenafil), is an oral phosphodiesterase-5 (PDE5) inhibitor—the same broad enzyme class as sildenafil (Viagra), though developed to cross into the central nervous system.
Because POLARIS-AD was structured with dual primary populations allowing success to be declared if either threshold hit, AriBio is treating the 52-week study as a positive trial and plans to seek talks with the U.S. Food and Drug Administration (FDA). Independent dementia researchers, however, are scrutinizing the gap between the monotherapy subgroup and the overall study pool.
